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In 1977, Rizzetto and coworkers discovered the
hepatitis D virus (HDV) while they were trying to
find out why some patients with hepatitis B virus
(HBV) infection had more serious disease than
others. A previously unrecognized antigen in the
liver cell nuclei of patients with hepatitis B surface
antigen (HBsAg)-positive chronic liver disease was
demonstrated, which they provisionally called the
delta antigen.1 Subsequent experiments revealed
that the delta antigen was a novel infectious agent
we now know as HDV.2 Classified within the new
genus Deltavirus,3 HDV is a subviral satellite with
HBV as its natural helper virus.2 Cloned and se-
quenced in 1986, HDV is the first and only ani-
mal virus to have a circular, single strand minus
RNA genome, which is a structural characteristic
and mode of replication that has only previously
been seen in plant viroids and virusoids.4–6
HDV Biology
Viral structure
On electron microscopy, HDV is an enveloped,
spherical, approximately 36 nm particle that con-
tains a RNA genome of about 1700 nucleotides,
the smallest animal viral genome.1,2 VThe HD
ygenome has the ability to fold into a partiall
double-stranded, unbranched, rod-shaped struc-
rture, reflecting the high degree of intramolecula
base-pairing due to high G +C content.4 VThe HD
fvirions possess an outer envelope composed o
r HBsAg proteins and host lipids, and an inne
nucleocapsid consisting of viral RNA and hepati-
tis delta antigen (HDAg). HDAg, the only HDV-
fencoded protein discovered so far, consists o
two protein species: a 27-kDa (214 amino acids)
g g ( g) (lar e HDA  L-HDA  and a 24-kDa 195 amino
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acids) small HDAg (S-HDAg), both from a single
coding open reading frame (ORF).7 The two
HDAgs are identical in sequence, except that the
L-HDAg contains an additional 19 amino acids
at the C-terminus.3
HDV viral life cycle
The replication cycle of HDV starts with the
attachment of the virus to the hepatocyte mem-
brane and ends with its release from the infected
cell. It is believed that HBsAg-mediated binding
to a cellular receptor helps HDV penetration into
the hepatocyte.8 Nuclear localization signal do-
main on HDAg further leads its genome into the
nucleus, where genome replication occurs.9
Replication of the RNA is proposed to occur by
a double-rolling-circle mechanism,5,6,10 similar to
that proposed for the replication of plant viroids
and small satellite RNAs of some plant viruses.11
During replication, three major species of RNA
exist in infected hepatocytes: genomic RNA (neg-
ative polarity), antigenomic RNA (positive polar-
ity), and a smaller polyadenylated RNA (0.8 kb)
of antigenomic polarity, which is the messenger
RNA (mRNA) containing the ORF for the syn-
thesis of HDAg.3 HDV has the unique ability to
utilize host RNA-dependent RNA polymerase to
transcribe the viral RNA genome directly without
a DNA intermediate.12 At first, the genomic RNA
serves as a template to synthesize multimeric lin-
ear transcripts of antigenomic polarity, which
undergo autocatalytic cleavage and ligation to pro-
duce circular monomeric antigenomic RNA.13 The
antigenomic RNA serves as the template for pro-
duction of more genomic RNA, which is processed
to produce the polyadenylated mRNA. S-HDAg,
the product of the unedited transcript, stabilizes
HDV RNA circle and promotes replication. The
antigenomic RNA can also be edited by intra-
cellular host dsRNA adenosine deaminase,14,15
resulting in a protein with an additional 19 amino
acids at the C-terminus, the L-HDAg. The L-HDAg
functions as a potent dominant negative inhibitor
of viral replication.3
Recent studies have shown that post-transla-
tional modifications of HDAg can modulate HDV
RNA replication. So far, the known post-transla-
tional modifications of HDAg include prenylation,
phosphorylation, acetylation and methylation.
 Prenylation of the cysteine residue within the
C-terminus of L-HDAg creates a lipophilic mole-
cule that binds to both HDV RNA and to HBsAg,
leading to membrane association, viral packag-
ing and release.16,17 gThe phosphorylation of HDA
 occurs at multiple residues, with serine-177
(S-177) being the major site. S-177 phospho-
rylation is required for efficient viral replication,
particularly the antigenomic RNA strand.18,19
The acetylation of HDAg may regulate the sub-
 cellular localization of HDAg and participate
in viral RNA nucleocytoplasmic shuttling and
replication.20 The methylation of S-HDAg is also
ressential for HDV RNA replication, especially fo
that of antigenomic RNA strand to form the ge-
nomic RNA strand.21
fExcept for its intrinsic autocatalytic activity o
genome cleavage and ligation, HDV utilizes and
redirects host cellular enzymes toward production
of its viral antigen and virions. The study of the
viral lifecycle can point to new targets for effec-
tive antiviral therapy, one example of which is
gthe development of anti-HDV drugs by inhibitin
HDAg isoprenylation.22
Seroepidemiology
HBV infection is a global health problem, and
over 350 million people around the world are
chronic carriers of the virus. It has been esti-
gmated that approximately 5% of the global HBsA
g carriers are also coinfected with HDV, leadin
to a total of 10–15 million HDV carriers world-
wide.23,24 A recent seroepidemiologic study in
Taiwan revealed that 5% of female prostitutes,
14% of intravenous drug users and 16% of male
prostitutes are anti-HDV-positive.25 In Italy, 8.3%
of HBsAg-positive patients in 14 liver referral units
were positive for anti-HDV.26 Chronic HDV infec-
tion is estimated to be responsible for more than
1000 deaths each year in the United States.27 High
grisk groups include HBsAg-positive parenteral dru
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users, female prostitutes and brothel-goers.26,28
Male prostitutes and immigrant prostitutes have
been identified as new “high-risk” populations
and may become a reservoir for disease transmis-
sion in HBV endemic areas.25 Overall, HDV infec-
tion is still an important public health problem
worldwide and remains a major cause of mortal-
ity and liver transplantation.
Geographic Distribution of HDV Infection
The geographic distribution of HDV infection
might be expected to mirror that of HBV. Never-
theless, the rate of HDV infection is not a simple
reflection of that of HBV infection.29 There are
areas with high prevalence of HBV infection but
relatively low prevalence, if any, of HDV infec-
tion, suggesting that other factors, such as age at
HBV infection, may determine the acquisition of
HDV infection. For example, in Alaskan Natives,
in which HBV infection occurs during infancy
and childhood, the prevalence of HDV infection
is negligible despite HBV endemicity. HDV ap-
pears to be endemic in the Middle East, but again
its distribution bears little relationship to that of
HBV.30 High prevalence areas of HDV infection
include Italy, some parts of Eastern Europe, the
Amazon basin, Venezuela, Columbia, some Pacific
Islands, Pakistan, and Western Asia.29,31–34 It is
estimated that each year, 7500 HDV infections
occur in the United States.32 New foci of infec-
tion have been identified in the island of Okinawa
in Japan,35 villages in China, northern India,36
and southern Albania.37 The subtropical area in
south America remains an important potential
reservoir for new outbreaks of HDV infection.38
Viral Heterogeneity
Longitudinal analysis of the evolution of HDV
RNA quasispecies during chronic infection revealed
that the mutation rate of HDV isolates ranges from
3 × 10−2 to 3 × 10−3 base substitutions per nucleo-
tide per year.39 Highly conserved domains have
been identified in the regions around the auto-
catalytic cleavage site of the genomic and antige-
fnomic RNA and the RNA-binding domain o
HDAg.40,41 Full-length RNA sequence comparisons
show up to 40% heterogeneity in genomic se-
quence variability among isolates collected world-
wide,42 and at least three genotypes have been
yidentified. HDV genotype may be determined b
restriction fragment length polymorphism analysis
yof polymerase chain reaction (PCR) products, b
direct sequencing, and by immunohistochemical
staining using genotype-specific anti-HDV anti-
bodies on liver biopsies.43
Being the most common genotype worldwide,
genotype 1 is associated with a broad spectrum
of pathogenicity.5,40,44 A recent study further re-
Vvealed that genotype 1 HDV and genotype C HB
tinfections were associated with the developmen
rof cirrhosis, hepatocellular carcinoma (HCC), o
mortality due to hepatic failure in chronic hepa-
titis D (CHD) patients.45 Within genotype 1, two
subtypes, 1A and 1B, have been identified. Subtype
1A is predominant in Asia, 1B in the United
States, and both are common in the Mediterranean
area. Isolates of genotype 2 were originally discov-
ered in Taiwan and Japan, where it is the pre-
dominant genotype. An association of genotype
2 with milder forms of liver disease in these areas
has been observed,46 which may be related to
fewer viral particles secretion due to lower pack-
age and editing efficiency, and hence less severe
hepatic inflammation.47 yGenotype 3 is exclusivel
found in countries from northern South America
(Columbia, Venezuela, Peru). It has been associ-
ated with outbreaks of severe and fulminant forms
of hepatitis. Interestingly, this genotype is linked
to the coexisting HBV genotype F.31,48,49 Unlike
Vgenotype 3, no particular linkage between HB
and HDV genotypes could be found in Taiwan.50
Besides epidemiologic interest, further studies are
necessary to clarify whether clinical differences
famong genotypes exist in terms of efficacy o
replication, packaging, infectivity, transmissibil-
ity and pathogenicity.
Furthermore, phylogenetic reconstructions
based on the HDAg gene and full-length genome
T.H. Hsieh, et al
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sequence data show an extensive and probably
ancient radiation of African lineages, indicating at
least seven major clades among HDV isolates.51 So
far, only one serotype of HDV has been identified.
Modes of Transmission
As it is enveloped by HBsAg, HDV has similar
transmission routes to those of HBV, with percu-
taneous exposure being the most efficient one.
Intravenous drug use is among the commonest
modes of HDV transmission in non-endemic
areas, such as in northern Europe and in the
United States. In the past, hemophiliacs and
polytransfused subjects were at increased risk of
acquiring HDV infection,52 but it has virtually
disappeared as a result of universal HBV vaccina-
tion and blood screening for HBsAg. Epidemio-
logic analysis suggests that sexual contact with
an HDV carrier is also an important route of
HDV transmission.53 High homology of HDV
nucleotide sequence between index patients and
their spouses provided additional molecular evi-
dence of a common source of HDV infection in
some couples.41 In HDV endemic areas, such as
the Mediterranean basin, the unapparent par-
enteral route of transmission accounts for most
cases of HDV transmission,54 with a trend to form
clusters among family members.55 In southern
Italy, cohabitation with an HDV carrier was iden-
tified as a major risk for HDV transmission.
Perinatal transmission of HDV is rare.
HDV: A Declining Disease?
A changing trend in the epidemiology of HDV
has been observed. For example, a decline in the
prevalence of both acute and CHD has been ob-
served in Southern Europe and Southeast Asia.
In addition, the occurrence of fresh and severe
forms of HDV infection has significantly de-
creased in Italy. It is postulated that current pa-
tients may represent cohorts infected years ago
who survived acute HDV infection.26,56 In Taiwan,
the prevalence of HDV infection among high-
risk subjects has also declined over the past two
decades. Active preventive measures against pro-
miscuity and sexually transmitted diseases, and
the introduction of disposable needles and sy-
ringes to eliminate the opportunities for equip-
ment sharing may have contributed to this
phenomenon.57 The estimated rate of decrease
among female prostitutes from 1988 to 2002 was
t4.2% per year. Male prostitutes and immigran
prostitutes have, in contrast, been identified as
the new high-risk populations in Taiwan, and
they may become a reservoir for disease trans-
mission.25 fIn brief, a decline in the prevalence o
HBsAg carriers due to universal HBV vaccina-
tion,58 improvement in socioeconomic condi-
tions, reduced family size, and changes in the
behavior of intravenous drug users and in sexual
practice in response to HIV infection have proba-
Vbly contributed to the declining incidence of HD
infection worldwide.23
Clinical Features and Diagnosis in
Different Situations
yAcute HDV infection can occur concurrentl  
twith HBV infection (coinfection) or in a patien
with established HBV infection (superinfection)
(Table 1). In patients with HDV coinfected with
HBV, a biphasic increase in serum aminotrans-
ferase activity has been commonly observed in
the clinical setting, which may help to differenti-
ate it from histologically indistinguishable acute
HBV infection. However, since no large study has
Vdemonstrated the proportion of cases of HD
coinfection presenting with such a clinical mani-
festation, the accuracy of using this feature to
 diagnose HBV and HDV coinfection remains
unproven. Although the clinical manifestations
of HDV and HBV coinfection may range from
mild to severe fulminant hepatitis,48 complete
clinical recovery from acute self-limiting disease
with no chronic sequelae is usually the rule. The
chance of HDV coinfection becoming chronic is
intrinsically limited because the chance of the
f fNatural course and treatment o  hepatitis D virus in ection
J Formos Med Assoc | 2006 • Vol 105 • No 11 873
helper virus HBV infection to become chronic is
also uncommon, occurring in less than 10% of
adult patients. Due to short-lived HDV, HDV in-
fection has little impact on the natural history of
HBV infection in this setting. The rate of chronic-
ity following coinfection with HBV and HDV is
equal to that of HBV infection alone.59
In HBV carriers superinfected with HDV, the
pre-existing HBsAg provides an ideal biologi-
cal substrate for HDV to complete its lifecycle.
Clinically, HDV superinfection may be divided
into three phases: acute phase, active HDV repli-
cation and suppression of HBV with high alanine
aminotransferase (ALT) levels; chronic phase, de-
creasing HDV and reactivating HBV with moder-
ate ALT levels; and late phase, development of
cirrhosis and HCC caused by replication of either
virus or remission resulting from marked reduc-
tion of both viruses.60 In general, in the acute
phase, HDV superinfected carriers may develop se-
vere hepatitis, and around 70–90% will progress
to chronicity.60 In patients with acute hepatitis 
A to E, HDV superinfection is also found to be
associated with a higher incidence of fulminant
hepatic failure.60–62 An Italian study showed that
HDV infection was found in 20 (90%) of the
22 HBV patients who presented with a rapidly
progressive course to cirrhosis.63 Furthermore,
cirrhosis developed in up to 70% of CHD pa-
tients in the superinfection setting, about 15%
within 1–2 years of disease onset.63 Liaw et al
tfound that the incidence of cirrhosis developmen
in CHD patients cumulated to 21% in the 5 years
following acute HDV superinfection.61 The above
evidence indicate that HDV infection plays an
important role in the progression of HBV-related
liver diseases. From another aspect, a low preva-
lence of HDV activity was noted in asympto-
matic carriers of HBsAg in another Taiwanese
study in the superinfection setting.64 In Taiwan,
rCHD patients with HCC were also not younge
than chronic hepatitis B patients with HCC.
Acquirement of HDV infection in middle-aged
adults through sexual contact with prostitutes
may account for the phenomenon in Taiwan,
rather than close family contact, or early intra-
venous drug abuse in Italy.65,66 VIn brief, HD  
superinfection is likely to become chronic sim-
ply because the HBV infection is already chronic.
Only a few patients have a self-limiting course
ywith subsequent clearance of HBV and HDV. B
providing HBsAg for HDV secretion and release,
tactive HBV replication may play an importan
frole by modulating the pathogenetic potential o
this defective agent.67 However, the complex inter-
play between HBV and HDV could explain the
Table 1. Clinical features of hepatitis D virus (HDV) coinfection and superinfection in hepatitis B virus (HBV) carriers
Coinfection Superinfection
HBV infection Acute Chronic
Outcomes Recovery with seroclearance Usually persistent infection
Markers
HBsAg Positive, early and transient Positive and persistent
IgM anti-HBc Positive Negative
Anti-HBs Positive in recovery phase Negative
HDV infection Acute Acute or chronic
Outcomes Recovery with seroclearance Usually persistent infection
Markers
Serum HDAg* Early and short-lived Early and transient, undetectable later
Liver HDAg Positive and transient Positive, maybe negative in late stage
Serum HDV RNA Positive, early and transient Positive, early and persistent
Anti-HDV Late acute phase, low titer Rapidly increasing, high titers
IgM anti-HDV Positive, transient, pentameric Rapidly increasing, high titers, monomeric
*Using immunoblot assay, detection rate of serum HDAg may be comparable to Northern blot detection of HDV RNA using cDNA probe.
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above controversial findings. Furthermore, persist-
ent HDV infection could also exert effective sup-
pression on HBV replication,62,64 with subsequent
HBeAg and HBsAg clearance.68 On the other hand,
decreasing level of HDV RNA with reappearance
of HBV DNA and progression of liver disease in
CHD patients has also been reported in Taiwan.60
Future studies are required to evaluate the exact
role of the individual viruses in the outcomes of
patients with dual HBV and HDV infection.
Currently, the most reliable tool to diagnose
HDV infection is based on highly sensitive mo-
lecular techniques, such as reverse transcription-
PCR. In acute HDV infection, serum HDV RNA 
is detectable in up to 90% of cases during the
symptomatic phase of the illness and becomes
undetectable after clinical resolution. Diagnosis
of HDV infection can also be achieved indirectly
based on the detection of antibodies against
HDAg (anti-HD) of immunoglobulin G (IgG) and
IgM classes in serum. Testing for IgM anti-HD is
crucial not only as a marker of primary HDV 
infection but also for its clinical relevance in the
natural history of the disease.69 During follow-
up, the decrease in or disappearance of monomeric
IgM anti-HD predicts resolution of chronic HDV
infection, either spontaneously or induced by 
interferon (IFN).70
In chronic HDV infection, the clinical features
are nonspecific. It cannot be easily distinguished
from chronic hepatitis of other etiologies based
on clinical manifestations alone. The correct di-
agnosis is suggested by a negative test for IgM
anti-HBc and confirmed by the detection of HDV
markers. Tests for HDV should be considered to
rule out coexistent chronic HDV infection in
HBsAg-positive patients with chronic active liver
disease, which is best achieved by screening for
anti-HDV antibody. CHD is associated with high
titers of both IgG and IgM anti-HD, although the
IgM are monomeric (7S), not pentameric (19S)
as in primary infection.69 In quiescent chronic
HDV infection, most patients have antibodies to
HBeAg and a low level of HBV replication,71,72
while HBV is suppressed.64 Serum HDV RNA can
be detected in only 60–75% of patients, and is 
Ta significant factor associated with elevated AL
levels and liver damage.60,71,73
Pathogenesis
The pathogenesis of HDV remains controversial.
In the acute stage, HDAg or HDV RNA may be di-
rectly cytotoxic to hepatocytes.74,75 tS-HDAg, bu
not L-HDAg, is directly cytotoxic to the cells when
expressed in large quantities.76–78 HDV genome
replication per se fcauses a modest inhibition o
the rate of cellular growth.74 In the chronic stage,74
inflammatory cells surround infected hepato-
cytes,79 and various autoantibodies have been
detected in the serum of patients with CHD, sug-
gesting the possible involvement of immune
responses in HDV pathogenesis.3 yLiver–kidne
tmicrosomal antibodies type 3 (LKM-3) agains
uridine diphosphate glucuronosyltransferases have
been particularly implicated in this aspect.80
Treatment
rPatients with CHD actually carry a much highe
risk of developing end-stage liver disease than
those with HBV alone. Although new HDV infec-
tion has declined in recent years, it is still impor-
tant to pay attention to this important issue and
consider active therapeutic intervention in exist-
ing patients with dual chronic hepatitis B and D.
Monotherapy
Interferon
tHDV-related chronic hepatitis is difficult to trea
(Table 2).81–91 rIFN is still the only therapy fo
CHD. The response to IFN varies widely and
roccurs at different time points, sometimes afte
discontinuation of IFN as in treating HBV patients.
The rate of response is generally proportional to
the dose of IFN, with 9 million units (MIU)
three times a week being more effective than 3
MIU thrice weekly.81 At the end of treatment,
Tnegativity of HDV RNA and normalization of AL
were 71% and 71%, respectively, in the high-dose
f fNatural course and treatment o  hepatitis D virus in ection
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group, compared to 36% and 29%, respectively,
in the low-dose group.81 Long-term serum ALT
normalization correlated with improved hepatic
function and loss of IgM anti-HDAg. Usually, re-
crudescence of hepatitis D viremia is the rule
after cessation of IFN treatment. The relapse is
often delayed, sometimes occurring more than 
a year after the completion of the course of
IFN.27 Although rare, sustained decrease in HDV
replication is possible in high-dose group and is
accompanied by the clearance of HDV RNA and
serum HBsAg, and seroconversion to anti-HBs.81
High doses of IFN-α-2a significantly improved
the long-term clinical outcome and survival of
patients with CHD.92 Striking improvement in
liver histology and even the disappearance of 
fibrosis were seen in patients who had an initial
diagnosis of active cirrhosis, and a long-term bio-
chemical response was observed.92–94 Although
short-standing disease might respond better to
therapy,95 ypredictors of response to IFN therap
are still unidentified.
Pegylated IFN
Recently, the development of pegylated-IFN (PEG-
IFN) with improved pharmacokinetics has been
shown to have better efficacy and convenience than
conventional IFNs,96,97 providing sustained viro-
Vlogic response (SVR; defined as undetectable HC
RNA at least 6 months after the end of treatment)
in 39% versus 17% of hepatitis C patients.97,98
Instead of fluctuating drug exposure, the sustained
action of PEG-IFN reduces the viral replication
that occurs on days without treatment during the
Table 2. Review of the treatment of chronic hepatitis D
Reference (yr) Patient Regimen Dosage
Duration BR (%) VR (%) SVR (%)
(wk) at EOT at EOT at EOFU
Farci et al81 (1994) CHD IFN-α-2a 9 MIU TIW 48 71 (10/14) 71 0
IFN-α-2a 3 MIU TIW 48 29 (4/14) 36 (5/14) 0
Gaudin et al82 (1995) CHD IFN-α-2b 5 MIU/m2 TIW, then 1st–16th
3 MIU/m2 TIW 17th–48th 66 (7/11) 66 9 (1/11)
Lau et al83 (1999) CHD Lamivudine 100 mg QD 48 0 (0/5) 0 0
Wolters et al84 (2000) CHD Lamivudine/ 100 mg QD 40 14 (1/7) 0 0
IFN-α 9 MIU QD, then 25th–28th
9 MIU TIW 29th–40th
Yurdaydin et al85 (2002) CHD Famciclovir 500 mg TID 24 0 1/15 0
Rosina et al86 (2002) CHD THF-γ2 40 μg QD, then 15 days 0 37 (3/8) 0
40 μg BIW 3rd–24th
Niro et al87 (2005) CHD Lamivudine 100 mg QD 52 0 (0/25) 8 (2/25)
Kaymakoglu et al88 CHD Ribavirin/IFN-α 1000–1200 mg QD 96 42 (8/19) 42 (8/19) 21 (4/19)
(2005) 10 MIU TIW
Gunsar et al89 (2005) CHD Ribavirin/ 1000–1200 mg QD 96 57 (12/21) 52 (11/21) 24 (5/21)
IFN-α-2a 9 MIU TIW
Castelnau et al90 (2006) CHD PEG-IFN-α-2b 1.5 μg/kg/wk 48 57 (8/14) 43 (6/14)
Niro et al91 (2006) CHD PEG-IFN-α-2b 1.5 μg/kg/wk 72 37 (6/16) 19 (3/16) 25 (4/16)
alone
PEG-IFN-α-2b/ 1.5 μg/kg/wk 72/48 41 (9/22) 9 (2/22) 18 (4/22)
ribavirin 800 mg/d
CHD = chronic hepatitis D; BR = biochemical response, defined by normalization of serum alanine aminotransferase; VR = virologic response, defined by 
the disappearance of HDV RNA in serum; SVR = sustained virologic response; EOT = end of treatment; EOFU = end of follow-up; THF-γ2 = thymic humoral
factor-γ2; QD = once per day; BID = twice per day; TID = three times per day; BIW = twice per week; TIW = three times per week.
standard thrice-weekly regimen of unmodified
IFN-α. In addition, the weekly dosing interval of
PEG-IFN makes it a convenient therapeutic op-
tion in the treatment of patients with CHD.
There has been very little experience with
PEG-IFN in the treatment of chronic hepatitis D
in the past. Persistent disappearance of HDV RNA
after 6 months of treatment with PEG-IFN-α-2a
in a previous nonresponder to conventional IFN
has recently been reported.99 In another study,
14 patients, 11 of whom had previously failed
treatment with standard IFN-α, completed 12
months of PEG-IFN-α-2b (1.5 μg/kg/week).90 Six
patients maintained SVR, defined as normaliza-
tion of serum ALT, negative HDV RNA, and IgM
anti-HDV at the end of follow-up. In a just pub-
lished prospective trial of PEG-IFN-α-2b alone
or in combination with ribavirin for the treat-
ment of CHD, 38 serum HBsAg- and HDV RNA-
positive patients with ALT more than 1.5 times
the upper limit of normal received PEG-IFN-α-
2b (1.5 μg/kg) alone as monotherapy (n = 16) or
in combination with ribavirin (n = 22) for 48
weeks.91 Thereafter, all the patients were main-
tained on PEG-IFN for 24 weeks and followed
for 24 weeks off therapy. At the end of follow-up,
serum HDV RNA was negative in eight (21%) 
patients, and a biochemical response was de-
tected in 10 (26%) patients. These results showed
that a prolonged course of PEG-IFN-α-2b re-
sulted in clearance of serum HDV RNA and ALT
normalization in a fifth of patients with chronic
hepatitis D, while ribavirin had no effect on viral
clearance rate.
Thymus-derived peptides
Apart from IFN, other monotherapeutic ap-
proaches have been unhelpful. In a study using
thymic humoral factor-γ2, none of the 11 patients
achieved normal serum ALT levels, and HDV
viremia relapsed in nine, one being negative at
baseline.86 Although free of IFN side effects, thy-
mosin-α1 was also not effective. Only two out of
six patients achieved HDV RNA clearance and
maintained ALT normalization at 12 months of
follow-up after thymosin-α1 therapy.100
Nucleoside analogs
tRibavirin, a nucleoside analog, is effective agains
RNA viruses. It has been shown to be effective in
inhibiting HDV genome replication in vitro,101 tbu
in vivo data from a small randomized controlled
trial were disappointing.102 TNo decrease in AL
level was observed, and all cases remained posi-
tive for serum HDV RNA and IgM anti-HD.102
Deoxynucleotide analogs
Deoxynucleotide analogs have also been used to
ginhibit HDV replication by repression of HBsA
production. In a pilot study, 6-month famci-
gclovir had no effect on disease activity, HBsA
levels, serum HDV RNA or lessening of the in-
flammation in the liver.85 tLamivudine is a poten
finhibitor of HBV DNA replication, but none o
the CHD patients receiving lamivudine 100 mg/
day for 1 year showed any improvement in dis-
Aease activity, liver histology or lower HDV RN
levels.83 Rarely, disease remission was observed
r in a patient after lamivudine 150 mg/day fo
28 months.103 In a recent multicenter randomized
controlled pilot study, only 8% of HDV patients
receiving lamivudine 100 mg/day for 52 weeks
achieved SVR.87 It is, thus, unlikely that lamivu-
 dine monotherapy is effective for HDV, but a
trecent study reported that lamivudine-resistan
VHBV mutants failed to efficiently support HD
secretion.104 Whether this interesting finding has
any clinical implication awaits to be elucidated.
Overall, available evidence does not support the
use of deoxynucleotide analogs.
Combination therapy
Although the optimal treatment choice for CHD
chas not yet been clarified, certain therapeuti
 concepts can be derived from the experience
Aof treating patients with chronic hepatitis C. 
major advancement in treating hepatitis C has
ybeen the development of combination therap
with PEG-IFN/IFN and ribavirin.105,106 VSince HC
and HDV are both hepatotropic RNA viruses, it is
ylogical to speculate that combination therapy ma
also potentiate the therapeutic effect of IFN in
HDV patients. However, a recent trial suggested
T.H. Hsieh, et al
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that ribavirin had no additive effect on viral
clearance rate.91
IFN plus ribavirin
HDV, like HCV, is a RNA virus. The combination
of IFN-α and ribavirin for 24 months in 19 CHD
patients resulted in normalization of ALT and
disappearance of HDV RNA in 42.1% and 42.1%,
respectively, at the end of treatment, and in 36.8%
and 21%, respectively, at the end of at least 
6 months of follow-up.88 Another small random-
ized controlled study comparing 2-year IFN ther-
apy with or without ribavirin in 31 CHD patients
showed normalization of ALT and disappearance
of HDV RNA in 57.1% and 52.4%, respectively,
at the end of treatment, and in 23.8% and 23.8%,
respectively, at the end of at least 6 months of
follow-up in the combination group.89 None of
the patients with liver cirrhosis were responsive
at the end of the follow-up period.89 Unlike its
overwhelming success in the treatment of HCV
patients, the combined regimen is not superior
to IFN-α monotherapy with regard to the clear-
ance of HDV RNA,88,89 despite its partial effec-
tiveness in improving the biochemical response
in these patients.
IFN plus acyclovir or lamivudine
In chronic HDV patients, there is no evidence
that acyclovir enhances IFN-based therapy.107 The
combination of lamivudine and 16 weeks of
high-dose IFN aimed at eradicating HDV was
also not successful. The decrease in serum HDV
RNA from baseline during treatment was not sig-
nificant, and all patients with improved ALT at
the end of treatment had biochemical rebound
after withdrawal of therapy.84
Further clinical trials are needed to clarify
whether PEG-IFN combined with other nucleo-
side/nucleotide analogs are more effective in treat-
ing CHD than conventional IFN-based therapy.
Novel options
Novel treatment options have been developed
based on the knowledge of the HDV lifecycle,
structure, and interaction with HBV.
RNA interference
tRNA interference (RNAi) has been utilized agains
viral infection, especially viral hepatitis. Nonethe-
less, among the three RNA species of HDV, i.e.
genomic, antigenomic, and delta antigen mRNA,
only the last can be successfully targeted by small
interfering RNA (siRNA) in cell culture.108 Regard-
ing this, it is considered that the genomic and
antigenomic RNAs are resistant to siRNA because
their location within the nucleus makes them in-
accessible to siRNA-mediated degradation.108 In
taddition, the endonuclease dicer cleaves RNAs tha
are 100% or nearly 100% double-stranded. There-
fore, despite the partial double-stranded rod-like
structure of genomic and antigenomic HDV RNAs,
gthe extended structure with only 74% base pairin
confers significant resistance to dicer action.109
Prenylation inhibitors
Previous research has demonstrated that preny-
lation of L-HDAg, one of the post-translational
modifications, is essential for viral assembly. In
HDV, prenylation inhibitors could have a dual
mechanism: inhibiting prenylation of a viral pro-
tein and the cellular pathways exploited by the
virus.110 Animal models have shown that preny-
glation inhibitors are highly effective at clearin
hepatitis D viremia, depending on the duration
of treatment.22 Steps in acetylation, methylation
and phosphorylation also reveal differential sub-
cellular domain targeting of the HDV protein
and could potentially shed light on the novel tar-
ygets for the treatment of HDV. Thus, molecularl
tailored drugs capable of interfering with crucial
viral replicative processes would appear to have
the most prospects in the treatment of HDV.
Prevention
Unlike HBV, screening of blood and blood prod-
ucts for HDV is considered unnecessary because
HDV cannot replicate in the absence of HBsAg.
Since tthe spread of HDV is closely linked with tha
of its helper virus, HBV, strategies that decrease the
incidence of HBV will result in a corre gspondin
decrease in HDV infection, implying that the ad-
ministration of universal HBV vaccination and
post-exposure prophylaxis will help to eliminate
HDV coinfection in the future. Education to reduce
high risk behaviors among persons with chronic
HBV infection will also reduce the incidence of
HDV superinfection. A recent mouse model study
has suggested that DNA vaccines against HDV can
induce significant cellular immune responses with
a T-helper 1 preference to prevent HDV superin-
fection.111 Since universal HBV vaccination has
effectively decreased the HBV carrier rate in the
general population, the development and role of
HDV vaccine is therefore not so compelling.112
Conclusion and Perspectives
HDV can be considered as a satellite of HBV.
Possibly more than any other infectious agent,
the replication of HDV is dependent on redirect-
ing host functions. Fortunately, HDV is vanish-
ing,26 probably owing to steps in the prevention
and treatment of HBV. Improvements in socio-
economic conditions, reduced family size, changes
in the behavior of intravenous drug users and
in sexual practice have also contributed to the
declining incidence of HDV infection worldwide.
Still, HDV RNA and its replication continue to be
a new and interesting issue in molecular biology.
Diagnosis relies on detection of antibodies against
HDAg and serum HDV RNA, as well as HBV
markers. Although fraught with adverse effects,
high-dose long-duration IFN is the only effective
modality of CHD treatment thus far. It is hoped
that in the near future, significant clarification of
the processes by which HDV replicate will be made,
thus offering more opportunities to treat HDV with
novel approaches at the molecular level.
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